Another strategy is to create a pseudoreceptor system using single-chain antibody fragments to retarget the virus to tumor-specific CD38, epidermal growth factor receptor (EGFR), or EGFR mutant vIII (EGFRvIII) [91]. This evidence concerns the gene EGFR and neoplasm.